Objective: To evaluate the treatment efficacy and tolerance of anti-human T lymphocyte porcine immunoglobulin (p-ALG) plus cyclosporine A (CsA) in acquired severe aplastic anemia (SAA). Method: Forty-eight SAA patients [31 males and 17 females; 17 with very SAA (VSAA)] were treated with p-ALG plus CsA and were analyzed retrospectively according to early mortality, response rate and quality, survival rate, toxicity, and complications. They were stratified further by gender, age, disease severity, interval from diagnosis to treatment, and preexisting infections. Result: The median age was 28 years (range 13–64). The interval from diagnosis to treatment was 45 days. The median neutrophil count was 0.178 × 109/l. The overall response was 83.3% (54.2% complete and 29.2% partial) with a 90-day median time (range 23–380), and 10.4% died of infection within 30 days. The 1.5-year survival was 87.5%. vSAA patients had less response, a higher early mortality, and less survival (64.7, 29.4, 51.8%) compared to SAA patients (93.5, 0, and 100%, respectively; p < 0.05). Groups with different age, gender, intervals between diagnosis and treatment, and preexisting infections had the same response. Mild toxicities were observed. Conclusion: p-ALG plus CsA is a reliable and well-tolerated treatment for SAA, and it has the great advantage of a much lower cost compared to horse/rabbit ATG. VSAA was a poor predictive factor for the response rate.

Keywords:
Anti-human T lymphocyte porcine immunoglobulin, Cyclosporine A, Severe aplastic anemia
1.
Brodsky RA, Jones RJ: Aplastic anemia. Lancet 2005;365:1647–1656.
2.
Young NS, Maciejewski J: The pathophysiology of acquired aplastic anemia. N Engl J Med 1997;336:1365–1372.
3.
British Committee for Standards in Haematology: Guidelines for the diagnosis and management of aplastic anaemia. 2009. http://www.bcshguidelines.com/pdf/published_AA_june10.pdf.
4.
Montané E, Ibanez L, Vidal X, Ballarín E, Puig R, García N, Laporte JR, the Catalan Group for the Study of Agranulocytosis and Aplastic Anemia: Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica 2008;93:518–523.
5.
Kaufman DW, Kelly JP, Levy M, Shapiro S: The Drug Etiology of Agranulocytosis and Aplastic Anemia. New York, Oxford University Press, 1991.
6.
Mary JY, Baumelou E, Guiguet M, the French Cooperative Group for Epidemiological Study of Aplastic Anemia: Epidemiology of aplastic anemia in France: a prospective multicenter study. Blood 1990;75:1646–1653.
7.
Cartwright RA, McKinney PA, Williams L, Miller JG, Evans DI, Bentley DP, Bhavnani M: Aplastic anaemia incidence in parts of the United Kingdom in 1985. Leuk Res 1988;12:459–463.
8.
Clausen N, Kreuger A, Salmi T, Storm-Mathisen I, Hohannesson G: Severe aplastic anaemia in the Nordic countries: a population based study of incidence, presentation, course, and outcome. Arch Dis Child 1996;74:319–322.
9.
Maluf EM, Pasquini R, Eluf JN, Kelly J, Kaufman DW: Aplastic anemia in Brazil: incidence and risk factors. Am J Hematol 2002;71:268–274.
10.
Yang C, Zhang X: Incidence survey of aplastic anemia in China. Chin Med Sci J 1991;6:203–207.
11.
Issaragrisil S, Kaufman DW, Anderson T, Chansung K, Leaverton PE, Shapiro S, Young NS: The epidemiology of aplastic anemia in Thailand. Blood 2006;107:1299–1307.
12.
Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H, the German Aplastic Anemia Study Group: Antithymocyte globulin with or without cyclosporine A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood 2003;101:1236–1242.
13.
Young NS, Bacigalupo A, Marsh JC: Aplastic anemia: pathophysiology and treatment. Biol Blood Marrow Transplant 2010;16 (suppl 1):119–125.
14.
Bacigalupo A, Bruno B, Saracco P, Di Bona E, Locasciulli A, Locatelli F, Gabbas A, Dufour C, Arcese W, Testi G, Broccia G, Carotenuto M, Coser P, Barbui T, Leoni P, Ferster A: Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. Blood 2000;95:1931–1934.
15.
Rosenfeid S, Follman D, Nunez O, Young NS: Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-time outcome. JAMA 2003;289:1130–1135.
16.
Chang MH, Kim KH, Kim HS, Jun HJ, Kim DH, Jang JH, Kim K, Jung CW: Predictors of response to immunosuppressive therapy with antithymocyte globulin and cyclosporine and prognostic factors for survival in patients with severe aplastic anemia. Eur J Haematol 2010;84:154–159.
17.
Zheng YZ, Chu YL, Shao ZH, Zhang YZ, Chen GB: Antilymphocyte globulin combining with cyclosporine A in the treatment of severe aplastic anemia. Zhonghua Xue Ye Xue Za Zhi 1999;20:175–177.
18.
He GS, Shao ZH, Zhang YZ, Liu H, Li K, Song LY, Zheng YZ, Chen GB, He H, Zhao MF, Shi J, Zhang H, Chu YL, Qian LS, Yang TY, Yang CL: Sequential intensified immunosuppressive therapy combining with hematopoietic growth factors in the treatment of severe aplastic anemia. Zhonghua Xue Ye Xue Za Zhi 2001;22:177–180.
19.
He GS, Shao ZH, Liu H, Zhang YZ, Chen GB, Li K, Song LY, He H, Zhao MF, Fu R, Shi J, Bai J, Zhang H, Chu YL, Yang TY, Yang CL: A long-term follow-up study of 50 patients with severe aplastic anemia who have survived more than 3 years after immunosuppressive therapy. Zhonghua Xue Ye Xue Za Zhi 2002;23:229–232.
20.
Teramura M, Kimura A, Iwase S, Yonemura Y, Nakao S, Urabe A, Omine M, Mizoguchi H: Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan. Blood 2007;110:1756–1761.
21.
Barcigalupo A, Broccia G, Corda G, Arcese W, Carotenuto M, Gallamini A, Locatelli F, Mori PG, Saracco P, Todeschini G, Coser P, Iacopino P, van Lint MT, Gluckman E, the European Group for Blood and Marrow Transplantation (EBMT) Working Party on SAA: Antilymphocyte globulin, cyclosporine, and granulocyte colony-stimulating factor in patients with acquired severe aplastic anemia (SAA): a pilot study on the EBMT SAA Working Party. Blood 1995;85:1348–1353.
22.
Locasciulli A, Arcese W, Locatelli F, Bona ED, Bacigalupo A, the Italian Aplastic Anaemia Study Group: Treatment of aplastic anaemia with granulocyte-colony stimulating factor and risk of malignancy. Lancet 2001;357:43–44.
23.
Scheinberg P, Wu CO, Nunez O, Young NS: Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol 2009;144:206–216.
24.
Ahn MJ, Choi JH, Lee YY, Choi IY, Kim IS, Yoon SS, Park SY, Kim BK, Suh C, Son HJ, Jung CW, Lee JH, Sung JM, Im SA, Oh D, Jung SY, Yoon HJ, Cho KS, Lee JA, Yuh YJ, Kim SR, Ki M: Outcome of adult severe or very severe aplastic anemia treated with immunosuppressive therapy compared with bone marrow transplantation: multicenter trial. Int J Hematol 2003;78:133–138.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.